Facebook Instagram Linkedin Youtube
Home Search

bibbinstruments - search results

If you're not happy with the results, please do another search
BiBBInstruments enters Sahlgrenska

BiBBInstrument’ founder on the Sahlgrenska evaluation

BibbInstruments reports Q3

BiBBInstrument’s CEO: “Distributors are contacting us”

Interest in BibbInstruments

BiBB comments on the growing interest in EndoDrill GI

BiBB's CEO: "Zagreb confirms good samples and short learning curve"

BiBB’s CEO: “Zagreb confirms good samples and short learning curve”

BiBBInstruments teknologi uppmärksammas i medicinsk tidskrift

BiBBInstruments’ technology gets nod in medical journal

Interest in BiBBInstruments’ EndoDrill GI continues to increase

Interest in BiBBInstruments’ EndoDrill GI continues to increase

EndoDrill seen as promising new EUS technology

EndoDrill seen as promising new EUS technology

BiBB’s CEO: “Patient cases fortify our confidence in EndoDrill”

BiBB’s CEO: “Patient cases fortify our confidence in EndoDrill”

BiBBInstruments utökar patentskyddet till Japan

BiBBInstruments expands patent protection to Japan

BIBB_Founder_CharlesWalther

BiBB’s founder on the first US clinical cases with EndoDrill

BiBB granted CE certification according to MDR

BiBB’s CEO: “European CE approval is a significant milestone”

BiBB premier

BiBBInstruments’ EndoDrill premier received with enthusiasm

BiBBInstruments vd: "Spännande tider väntar"

BiBBInstruments’ CEO: “Exciting times ahead”

BiBBIntruments_CharlesWalther

BiBB Founder’s Quest to Transform Cancer Diagnostics

BiBBInstruments strong Q2

BiBB coming off strong first half of 2023

BiBBInstruments MIBC results

BiBB’s CMO comments on promising results in bladder cancer

New Opportunities for BiBBInstruments

Full speed ahead for BiBBInstruments after FDA clearance

BiBBInstruments FDA tailwinds

FDA tailwinds for BiBBInstruments

BiBBInstruments_FDA_Clearance

FDA clearance opens US market for BiBBInstruments

BiBBInstruments pankreascancer

BiBBInstruments aims to revolutionise pancreatic cancer diagnostics

BiBBInstruments blickar fram mot händelserikt 2023

BiBBInstruments eyes an eventful 2023

Elicera Therapeutics receives important EU patent

BiBBInstruments comments on upcoming patent approval

BiBBInstruments Q3 2022

BiBBInstruments comments on its Q3 report

BiBB ready for action

BiBBInstruments ready for active near-term future

Bibb completes bladder cancer study

BiBBInstruments completes bladder cancer study

BiBBInstruments FDA 2022

BiBBInstruments aims for US market entry in 2023

BiBB Digestive disease week

BiBBInstruments successfully participated in DDW conference

BiBBInstruments

Strengthened financial muscle for BiBBInstruments

BiBBInstruments Endoscopic Ultrasound

BiBBInstruments at forefront of cancer diagnostics revolution

BiBBInstruments Capital Raise

BiBBInstruments kicks off 2022 with capital raise

Key steps taken by BiBBInstruments in 2021

Key steps taken by BiBBInstruments in 2021

BiBBInstruments’ cancer study comes to early end after convincing data

BiBBInstruments’ cancer study comes to early end after convincing data

BiBBInstruments continues to lay groundwork for commercialisation

BiBBInstruments continues to lay groundwork for commercialisation

BibbInstruments Market Opportunity

BibbInstruments aims high in cancer diagnostics industry

Show of resilience from BiBBInstruments during Q2

BiBBInstruments resumes key clinical trials

BiBBInstruments remains optimistic despite temporary pause in studies

BiBBInstruments submits third international patent application

BiBBInstruments initiates clinical trial in bladder cancer

BiBBInstruments brings new vision to cancer diagnostics

Start

© BioStock 2024